Article
Anecortave acetate proving helpful for inhibiting CNV growth
Anaheim, CA-Anecortave acetate (Retaane, Alcon), a potent angiostatic agent, has been shown to be safe and superior to placebo in reducing loss of vision from baseline, avoiding severe vision loss, and inhibiting the growth of CNV membranes in patients with age-related macular degeneration (AMD), according to Jason S. Slakter, MD, who spoke during the American Academy of Ophthalmology annual meeting.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
